Analysts: 'High Risk, High Reward'
Targanta Revives Oritavancin: Next Weapon Against cSSSI?
By Randall Osborne
Monday, November 26, 2007
Remember FDA-stalled oritavancin? The hospital-based glycopeptide antibiotic acquired in 2001 by InterMune Inc. from Eli Lilly and Co. (which developed the compound as a replacement for vancomycin, which still takes an estimated 80 percent share of the market) was bought by Targanta Therapeutics Inc around Christmas four years later. (BioWorld Financial Watch)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.